natgillin/translations-raw huggingface dataset:
Maternal hepatitis B is not a contraindication to breast-feeding if the newborn is adequately managed for hepatitis B prevention at birth, and there is no evidence that the low concentration of lamivudine in human milk leads to adverse reactions in breastfed infants.
Hepatitis B kod majke nije kontraindikacija za dojenje ako je prilikom rođenja provedena primjerena prevencija hepatitisa B kod novorođenčeta i nema dokaza da niska koncentracija lamivudina u humanom mlijeku dovodi do nuspojava u dojenčeta.
- Baseline normal above normal
- početne vrijednosti normalne više od normalnih
Renal clearance accounts for about 70 % of lamivudine elimination.
Bubrežnim klirensom eliminira se oko 70% lamivudina.
- Week 260 4 negative positive < baseline positive > baseline
- 260. tjedan4 negativne pozitivne < početnih pozitivne > početnih
Data is available from an extended treatment study in HBeAg negative patients (NUCAB3017) treated with lamivudine.
Dostupni su podaci iz ispitivanja produljenog liječenja HbeAg negativnih bolesnika (NUCAB3017) liječenih lamivudinom.
Continued lamivudine treatment for an additional 2 years in patients who had failed to achieve HBeAg seroconversion in the initial 1 year controlled studies resulted in further improvement in bridging fibrosis.
Nastavak liječenja lamivudinom tijekom daljnje 2 godine u bolesnika u kojih nije došlo do serokonverzije HBeAg u inicijalnim jednogodišnjim kontroliranim ispitivanjima doveo je do daljnjeg poboljšanja premoštavajuće fibroze.
100 mg once daily, Cmax is in the order of 1.1-1.5 µg/ml and trough levels were 0.015-0.020 µg/ml.
Pri terapijskim dozama, npr. 100 mg jedanput na dan, Cmax se kreće u vrijednostima od 1,1 do 1,5 µg/ml dok su najniže koncentracije lijeka 0,015-0,020 µg/ml.
Table 1: Dosage of Zeffix in patients with decreased renal clearance.
Tablica 1: Doziranje lijeka Zeffix za bolesnike sa smanjenim bubrežnim klirensom
Following HBeAg seroconversion, serologic response and clinical remission are generally durable after stopping lamivudine.
Nakon serokonverzije HbeAg, serološki odgovor i klinička remisija općenito traju i nakon prestanka uzimanja lamivudina.
Allergic reaction These are rare (may affect up to 1 in 1,000 people).
One su rijetke (mogu se javiti u do 1 na 1000 osoba).
A comparison of post-treatment ALT elevations between weeks 52 and 68 in patients who discontinued lamivudine at week 52 and patients in the same studies who received placebo throughout the treatment course is shown in Table 3.
Usporedba porasta razina ALT nakon liječenja, između 52. i 68. tjedna, u bolesnika koji su prestali uzimati lamivudin u 52. tjednu i bolesnika iz istih ispitivanja koji su dobivali placebo tijekom razdoblja liječenja prikazana je u Tablici
In patients who do not maintain a sustained serological response, consideration should be given to retreatment with either lamivudine or an alternative antiviral agent for resumption of clinical control of HBV.
U bolesnika u kojih se ne održi serološki odgovor, treba razmotriti ponovno uvođenje lamivudina ili nekog drugog protuvirusnog lijeka u cilju ponovnog uspostavljanja kliničke kontrole HBV-a.
Side effects that were commonly reported in Zeffix clinical trials were tiredness, respiratory tract infections, throat discomfort, headache, stomach discomfort and pain, nausea, vomiting and diarrhoea, increases in liver enzymes and enzymes produced in the muscles (see below).
Nuspojave koje su često zabilježene u kliničkim ispitivanjima s lijekom Zeffix bile su umor, infekcije dišnih puteva, neugoda u grlu, glavobolja, neugoda i bol u želucu, mučnina, povraćanje i proljev, povišene vrijednosti jetrenih enzima i enzima koje proizvode mišići (pogledajte tekst ispod).
The standard recommended procedures for hepatitis B virus immunisation in infants should be followed.
Treba slijediti standardne preporuke za imunizaciju djece protiv hepatitisa B.
Improvement in bridging fibrosis occurred in 19/30 (63 %) patients without YMDD mutant and 22/44 (50 %) patients with the mutant.
Poboljšanje premoštavajuće fibroze nastupilo je u 19/30 (63 %) bolesnika bez YMDD tipa virusa i 22/44 (50 %) bolesnika s YMDD tipom virusa.
Substances shown to be predominately excreted either via the active organic anionic pathway, or by glomerular filtration are unlikely to yield clinically significant interactions with lamivudine.
Mala je vjerojatnost da bi tvari koje se pretežno izlučuju aktivnim organskim anionskim putem ili glomerularnom filtracijom doprinijele klinički značajnim interakcijama s lamivudinom.
There have been reports of mitochondrial dysfunction in infants exposed in utero and/or post-natally to nucleoside analogues (see section 4.4).
Također postoje izvješća o disfunkciji mitohondrija u djece izložene nukleozidnim analozima in utero i/ili postnatalno (vidjeti dio 4.4).
Based on these data, no dose adjustment is necessary in patients with hepatic impairment unless accompanied by renal impairment.
Temeljem tih podataka, nije potrebno prilagođavati dozu u bolesnika s oštećenjem jetre osim ako ono nije udruženo s oštećenjem bubrega.
Zeffix oral solution is supplied in cartons containing a white polyethylene bottle, with a child resistant cap.
Zeffix oralna otopina dolazi u kutiji koja sadrži bijelu polietilensku bocu sa sigurnosnim zatvaračem za djecu.
Lamivudine had no effect on the pharmacokinetics of trimethoprim or sulphamethoxazole.
Lamivudin ne utječe na farmakokinetiku trimetoprima ili sulfametoksazola.
Lamivudine is predominately cleared by renal excretion of unchanged substance.
Lamivudin se pretežno izlučuje renalnim izlučivanjem nepromijenjenog lijeka.
Butterscotch coloured, film-coated, capsule shaped, biconvex, approximate dimensions 11mm x 5mm and engraved “GX CG5” on one face.
Svijetlosmeđa, bikonveksna, filmom obložena tableta oblika kapsule, dimenzija približno 11 mm x 5 mm, s utisnutom oznakom “GX CG5” na jednoj strani.
Don't stop taking Zeffix
Nemojte prestati uzimati Zeffix
Zeffix film-coated tablets are supplied in tamper evident foil blisters containing 28 or 84 tablets.
Zeffix filmom obložene tablete su dostupne u blister pakiranju s evidencijom prvog otvaranja koji sadrži 28 ili 84 tablete.
In patients followed for up to 16 weeks after discontinuation of treatment at one year, post-treatment ALT elevations were observed more frequently in patients who had received lamivudine than in patients who had received placebo.
U bolesnika praćenih do 16 tjedana nakon prestanka jednogodišnjeg liječenja porast razina ALT nakon liječenja češće je zabilježen u bolesnika koji su dobivali lamivudin nego u onih koji su dobivali placebo.
The main adverse events reported are haematological disorders (anaemia, neutropenia), metabolic disorders (hyperlipasemia).
Najčešće prijavljene nuspojave su hematološki poremećaji (anemija, neutropenija) i metabolički poremećaji (povišena razina lipaza).
Zidovudine had no effect on the pharmacokinetics of lamivudine (see section 5.2).
Zidovudin ne utječe na farmakokinetiku lamivudina (vidjeti dio 5.2).
As anticipated due to the concomitant immunosuppression, the rate of emergence of YMDD mutant HBV after 52 weeks treatment was higher (36 % - 64 %) in the liver transplant population than in the immunocompetent CHB patients (14 % - 32 %).
Kako se i očekivalo, zbog istodobne imunosupresije, stopa pojave YMDD tipa virusa nakon 52 tjedna bila je veća u bolesnika s transplantiranom jetrom (36%-64%) nego u imunokompetentnih bolesnika s kroničnim hepatitisom B (14%-32%).
Exacerbations in patients with decompensated cirrhosis Transplantation recipients and patients with decompensated cirrhosis are at greater risk from active viral replication.
Primatelji transplantiranih organa i bolesnici s dekompenziranom cirozom pod većim su rizikom od aktivne replikacije virusa.
Furthermore, lamivudine-TP has little effect on mammalian cell DNA content.
Nadalje, lamivudin-trifosfat ima mali učinak na sadržaj DNK u stanicama sisavaca.
Glaxo Operations UK Limited (trading as Glaxo Wellcome Operations) Harmire Road
Glaxo Operations UK Limited (posluje kao Glaxo Wellcome Operations) Harmire Road
compensated liver disease with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active liver inflammation and/or fibrosis.
• kompenziranom bolešću jetre i dokazanom aktivnom replikacijom virusa, trajno povišenim razinama alanin aminotransferaze (ALT) u serumu i histološki dokazanom aktivnom upalom jetre i/ili fibrozom.
Moreover, Zeffix should not be taken with any other medicinal products containing lamivudine (see section 4.4).
Osim toga, Zeffix se ne smije uzimati s drugim lijekovima koji sadrže lamivudin (vidjeti dio 4.4).
Given the risk of YMDD mutant HBV, maintenance of lamivudine monotherapy is not appropriate in patients with detectable serum HBV DNA at or beyond 24 weeks of treatment (see section 4.4).
S obzirom na rizik od YMDD mutiranog virusa HBV, održavanje monoterapije lamivudinom nije primjereno u bolesnika s detektabilnim HBV DNK u serumu nakon 24 tjedna liječenja ili dulje od toga (vidjeti dio 4.4).
Sucrose 20 % w/v (4 g/20 ml) Methyl parahydroxybenzoate (E218) 1.5 mg/ml Propyl parahydroxybenzoate (E216) 0.18 mg/ml
saharoza 20 % m/V (4 g/20 ml) metilparahidroksibenzoat (E218) 1,5 mg/ml propilparahidroksibenzoat (E216) 0,18 mg/ml
This population primarily consisted of children with minimal hepatitis B. A dose of 3 mg/kg once daily (up to a maximum of 100 mg daily) was used in children aged 2 to 11 years and a dose of 100 mg once daily in adolescents aged 12 years and above.
Djeca od 2 do 11 godina dobivala su dozu od 3 mg/kg jedanput na dan (do maksimalno 100 mg na dan), dok su adolescenti u dobi od 12 godina i više dobivali dozu od 100 mg jedanput na dan.
Keep in touch with your doctor, and don't stop taking Zeffix without your doctor's advice.
Budite u kontaktu sa svojim liječnikom i nemojte prestati uzimati Zeffix ako Vam to nije savjetovao liječnik.
• In patients with HBeAg positive chronic hepatitis B (CHB) without cirrhosis, treatment should be administered for at least 6-12 months after HBeAg seroconversion (HBeAg and HBV DNA loss with HBeAb detection) is confirmed, to limit the risk of virological relapse, or until HBsAg seroconversion or there is loss of efficacy (see section 4.4).
• U HBeAg pozitivnih bolesnika s kroničnim hepatitisom B, a bez ciroze, liječenje treba provoditi najmanje 6 - 12 mjeseci nakon potvrđene serokonverzije HBeAg (gubitak HBeAg i HBV DNK uz pojavu HBeAb), kako bi se ograničio rizik od relapsa virusa, odnosno do serokonverzije HBsAg ili do gubitka djelotvornosti (vidjeti dio 4.4).
The most common adverse reactions reported were malaise and fatigue, respiratory tract infections, throat and tonsil discomfort, headache, abdominal discomfort and pain, nausea, vomiting and diarrhoea.
Najčešće zabilježene nuspojave bile su malaksalost i umor, infekcije dišnih puteva, nelagoda u predjelu grla i tonzila, glavobolja, bol i nelagoda u trbuhu, mučnina, povraćanje i proljev.
Lamivudine is metabolised by both infected and uninfected cells to the triphosphate (TP) derivative which is the active form of the parent compound.
Lamivudin se metabolizira i u zaraženim i u nezaraženim stanicama u trifosfatni derivat koji je aktivni oblik osnovnog spoja.
Therefore breastfeeding may be considered in breastfeeding mothers being treated with lamivudine for HBV taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Stoga dojenje treba razmotriti u dojilja liječenih lamivudinom zbog HBV-a, pritom uzimajući u obzir prednosti dojenja za dijete i prednosti terapije za majku.
Lamivudine-TP acts as a substrate for the HBV viral polymerase.
Lamivudin-trifosfat djeluje kao supstrat virusne polimeraze HBV-a.
The incidence of YMDD mutant HBV was similar to that observed in adults, ranging from 19 % at week 52 up to 45 % in patients treated continuously for 24 months.
Incidencija YMDD tipa virusa bila je slična onoj u odraslih i kretala se od 19% u 52. tjednu do 45% u bolesnika koji su kontinuirano liječeni tijekom 24 mjeseca.
For HIV co-infected patients not requiring anti-retroviral therapy, there is a risk of HIV mutation when using lamivudine alone for treating chronic hepatitis B.
U bolesnika zaraženih HIV-om kojima nije potrebna antiretrovirusna terapija postoji rizik od mutacije HIV-a pri monoterapiji lamivudinom za liječenje kroničnog hepatitisa B.
For lamivudine-treated patients, the majority of post-treatment ALT elevations occurred between 8 and 12 weeks post-treatment.
U bolesnika liječenih lamivudinom, porast vrijednosti ALT najčešće je zabilježen u razdoblju između 8 i 12 tjedana nakon liječenja.
3 Abbott Genostics solution hybridisation assay (LLOD < 1.6 pg/ml 4 Chiron Quantiplex assay (LLOD 0.7 Meq/ml)
Abbott Genostics hibridizacijski test u otopini (LLOD < 1,6 pg/ml) 4. Chiron Quantiplex test (LLOD 0,7 Meq/ml)
In patients with compensated liver disease, these increases in serum ALT were generally not accompanied by an increase in serum bilirubin concentrations or signs of hepatic decompensation.
U bolesnika s kompenziranom bolešću jetre taj porast serumskih razina ALT obično nije bio popraćen povišenim razinama bilirubina u serumu ili znakovima dekompenzacije jetre.
Zeffix is used to treat long term (chronic) hepatitis B infection in adults.
Zeffix se primjenjuje za liječenje dugotrajne (kronične) infekcije hepatitisa B u odraslih bolesnika.
A side effect which may show up in blood tests is:
Druge nuspojave koje se mogu javiti u krvnim pretragama su:
4 Turn the bottle upside down.
Okrenite bocu naopako.
Co-administration of sorbitol solution (3.2 g, 10.2 g, 13.4 g) with a single 300 mg dose (Adult HIV daily dose) of lamivudine oral solution resulted in dose-dependent decreases of 14%, 32%, and 36% in lamivudine exposure (AUC) and 28%, 52%, and 55% in the Cmax of lamivudine in adults.
Istodobna primjena otopine sorbitola (3,2 g, 10,2 g, 13,4 g) s jednom dozom od 300 mg (dnevna doza za odrasle osobe s HIV-om) oralne otopine lamivudina rezultirala je o dozi ovisnim smanjenjem od 14%, 32% i 36% u izloženosti lamivudinu (AUC∞) i 28%, 52% i 55% u Cmax lamivudina kod odraslih osoba.
The incidence of adverse reactions and laboratory abnormalities (with the exception of elevations of ALT and CPK, see below) were similar between placebo and lamivudine treated patients.
Incidencija nuspojava i poremećaja laboratorijskih vrijednosti (s izuzetkom povišenih razina ALT i CK, vidjeti daljnji tekst) bila je podjednaka u bolesnika liječenih lamivudinom i onih koji su dobivali placebo.
Experience in patients with decompensated liver disease Placebo controlled studies have been regarded as inappropriate in patients with decompensated liver disease, and have not been undertaken.
Iskustvo u bolesnika s dekompenziranom bolešću jetre Placebom-kontrolirana ispitivanja ne smatraju se primjerenima za bolesnike s dekompenziranom bolešću jetre te nisu ni provedena.
Lamivudine serum concentrations (AUC) are increased in patients with moderate to severe renal impairment due to decreased renal clearance.
Koncentracije lamivudina u serumu (AUC) povišene su u bolesnika s umjerenim do teškim oštećenjem funkcije bubrega zbog smanjenog bubrežnog klirensa.
The rate of overall disease progression in the lamivudine group was higher for subjects with detectable YMDD mutant HBV DNA (23/209, 11 %) compared to those without detectable YMDD mutant HBV (11/221, 5 %).
Stopa ukupne progresije bolesti u skupini koja je dobivala lamivudin bila je viša u bolesnika s detektibilnim YMDD tipom virusa HBV DNK (23/209, 11%) u odnosu na bolesnike bez detektibilnog YMDD tipa virusa (11/221, 5%).
EU/1/99/114/002 84 tablets
EU/1/99/114/001 28 tableta EU/1/99/114/002 84 tablete
Zeffix is indicated for the treatment of chronic hepatitis B in adults with:
Zeffix je indiciran za liječenje kroničnog hepatitisa B u odraslih bolesnika s:
In some patients the development of YMDD mutant HBV can lead to exacerbation of hepatitis, primarily detected by serum ALT elevations and re-emergence of HBV DNA (see section 4.2).
U nekih bolesnika razvoj YMDD tipa virusa može izazvati egzacerbaciju hepatitisa što se prvenstveno otkriva porastom serumskih razina ALT i ponovnim pojavljivanjem HBV DNK (vidjeti dio 4.2).
If overdose occurs the patient should be monitored and standard supportive treatment applied as required.
U slučaju predoziranja potrebno je pratiti bolesnika i primjenjivati standardne suportivne mjere.
Nucleoside and nucleotide analogues have been demonstrated in vitro and in vivo to cause a variable degree of mitochondrial damage.
Analozi nukleozida i nukleotida su u in vitro i in vivo uvjetima pokazali sposobnost uzrokovanja različitih stupnjeva mitohondrijskih oštećenja.
Zeffix should not be taken with any other medicinal products containing lamivudine or medicinal products containing emtricitabine (see section 4.5).
Zeffix se ne smije uzimati s drugim lijekovima koji sadrže lamivudin ili lijekovima koji sadrže emtricitabin (vidjeti dio 4.5).
Zeffix helps to control your hepatitis B infection.
Zeffix pomaže u kontroli infekcije hepatitisa B.
In elderly patients the pharmacokinetic profile of lamivudine suggests that normal ageing with accompanying renal decline has no clinically significant effect on lamivudine exposure, except in patients with creatinine clearance of < 50 ml/min (see section 4.2).
Farmakokinetički profil lamivudina u starijih bolesnika pokazuje da smanjenje funkcije bubrega uslijed normalnog procesa starenja nema klinički značajnog utjecaja na izloženost lamivudinu, osim u bolesnika s klirensom kreatinina < 50 ml/min (vidjeti dio 4.2).
Film-coated tablet:
Filmom obložene tablete:
In elderly patients, normal ageing with accompanying renal decline has no clinically significant effect on lamivudine exposure, except in patients with creatinine clearance of < 50 ml/min.
U starijih bolesnika normalno starenje praćeno slabljenjem bubrežne funkcije nema klinički značajnog utjecaja na izloženost lamivudinu, osim u bolesnika s klirensom kreatinina < 50 ml/min.
If you are diabetic, please note that each dose of Zeffix (100 mg = 20 ml) contains 4 g of sucrose.
Ako ste dijabetičar, uzmite u obzir da svaka doza lijeka Zeffix (100 mg = 20 ml) sadrži 4 g saharoze.
Talk to your doctor if any of these apply to you.
Razgovarajte sa svojim liječnikom ako se nešto od toga odnosi na Vas.
In an extended treatment study in Asian patients (NUCB3018) the HBeAg seroconversion rate and ALT normalisation rate at the end of the 5 year treatment period was 48 % (28/58) and 47 % (15/32), respectively.
U produljenom ispitivanju u azijskih bolesnika (NUCB3018) stopa serokonverzije HbeAg nakon 5 godina liječenja iznosila je 48% (28/58), a stopa normalizacije ALT 47 % (15/32).
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking Zeffix.
Ako Vam je liječnik rekao da ne podnosite neke šećere, savjetujte se s liječnikom prije uzimanja lijeka Zeffix.
HBeAg seroconversion
Serokonverzija
- Baseline ALT  1 x ULN2 - Baseline ALT > 2 x ULN
- početni ALT ≤ 1 x GGN2 - početni ALT > 2 x GGN
Data are limited on the use of lamivudine in HBeAg negative (pre-core mutant) patients and in those receiving concurrent immunosuppressive regimes, including cancer chemotherapy.
Ograničeni su podaci o uporabi lamivudina u HBeAg negativnih ("divlji tip" virusa) bolesnika i u bolesnika koji se istodobno liječe imunosupresivnim lijekovima, uključujući i kemoterapiju karcinoma.
• medicines (usually liquids) containing sorbitol and other sugar alcohols (such as xylitol, mannitol, lactitol or maltitol), if taken regularly
• lijekovi (obično tekućine) koji sadrže sorbitol i druge šećerne alkohole (poput ksilitola,
Diabetic patients should be advised that each dose of oral solution (100 mg = 20 ml) contains 4 g of sucrose.
Bolesnike s dijabetesom treba upozoriti da svaka doza oralne otopine (100 mg = 20 ml) sadrži 4 g saharoze.
This degree of viral suppression was maintained (follow-on study NUC20917) with combined therapy during the second year of treatment to week 104 and most patients had improved markers of liver function and continued to derive clinical benefit.
Ovaj stupanj viralne supresije je održan (slijedom studije NUC20917) s kombiniranom terapijom tijekom druge godine terapije do 104 tjedna te se kod većine bolesnika poboljšala razina markera jetrene funkcije, kao i nastavak ostvarivanja kliničke dobrobiti.
Data obtained in patients with hepatic impairment, including those with end-stage liver disease awaiting transplant, show that lamivudine pharmacokinetics are not significantly affected by hepatic dysfunction.
Podaci za bolesnike s oštećenjem jetre, uključujući i one s terminalnim stadijem bolesti koji čekaju transplantaciju, pokazuju da poremećaj funkcije jetre ne utječe značajno na farmakokinetiku lamivudina.
If Zeffix is discontinued, patients should be periodically monitored both clinically and by assessment of serum liver function tests (ALT and bilirubin levels), for at least four months, and then as clinically indicated.
U slučaju prestanka liječenja lijekom Zeffix, bolesnike treba periodički podvrgavati i kliničkim pregledima i analizi jetrene funkcije (razine ALT i bilirubina u serumu) u razdoblju od najmanje četiri mjeseca, a nakon toga ukoliko je klinički indicirano.
Acute exacerbation of hepatitis has been observed in patients who have discontinued hepatitis B therapy and is usually detected by serum ALT elevations and re-emergence of HBV DNA.
Akutna egzacerbacija hepatitisa zabilježena je u bolesnika koji su prekinuli terapiju hepatitisa B, a obično se otkriva temeljem porasta serumskih razina ALT i ponovnog pojavljivanja HBV DNK.
Don't take this medicine after the expiry date shown on the bottle and the carton.
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na boci i kutiji iza oznake „EXP“.
However, the extent (based on the AUC) of lamivudine absorbed was not influenced, therefore lamivudine can be administered with or without food.
Međutim, hrana ne utječe na apsorbiranu količinu lamivudina (na temelju AUC) te se lamivudin može uzimati neovisno o obroku.
When lamivudine therapy was continued post transplantation there was reduced graft re-infection by HBV, increased HBsAg loss and on one-year survival rate of 76 - 100 %.
Kad se liječenje lamivudinom nastavilo i nakon transplantacije došlo je do smanjenja reinfekcije transplantata HBV-om, povećanog gubitka HBsAg, a stopa jednogodišnjeg preživljavanja iznosila je
First dose of Zeffix oral solution *
Prva doza Zeffix oralne otopine*
• an increase in the level of some liver enzymes (transaminases), which may be a sign of inflammation or damage in the liver.
• povišene vrijednosti jetrenih enzima (transaminaze), što može upućivati na upalu ili oštećenje jetre
Further results from the trial by YMDD mutant status are summarised in Table 2.
Ostali rezultati ispitivanja navedeni su u Tablici 2. prema statusu YMDD tipa virusa.
Lamivudine-TP does not interfere with normal cellular deoxynucleotide metabolism.
Lamivudin-trifosfat ne interferira s normalnim staničnim metabolizmom deoksinukleotida.
The recommended dosage of Zeffix is 100 mg once daily.
Preporučena doza lijeka Zeffix je 100 mg jedanput na dan.
Side effects thought to be caused by Zeffix
Nuspojave za koje se smatra da su uzrokovane lijekom Zeffix:
Confirmed HBeAg seroconversion occurred in 47 % (118/252) of subjects treated with lamivudine and 93 % (320/345) of subjects receiving lamivudine became HBV DNA negative (VERSANT [version 1], bDNA assay, LLOD < 0.7 MEq/ml) during the study.
Serokonverzija HbeAg potvrđena je u 47% (118/252) bolesnika liječenih lamivudinom, a 93% (320/345) bolesnika liječenih lamivudinom postalo je tijekom ispitivanja HBV DNK negativno (VERSANT [verzija 1], bDNK test, LLOD < 0.7 Meq/ml).